Filing Flows › ELI Lilly (LLY) › Q3 2026
ELI Lilly (LLY) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
ELI Lilly (LLY) reported revenue of $24.4B for the third quarter 2026 (Q3 2026), +39% from a year earlier and +6% from the quarter before. Operating margin was 34.5%, net earnings $6.5B (26.4% of revenue).
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.4B | +6% | +39% |
| Operating profit | $8.4B | -9% | +16% |
| Net earnings | $6.5B | -9% | +16% |
| Operating cash flow | $11.4B | +7% | +29% |
| Free cash flow | $8.2B | +6% | +22% |
What changed
Revenue was $24.4B in Q3 2026, up 39% year over year and up 6% from the previous quarter. Mounjaro was the largest line at 44% of revenue. Mounjaro added $4.2B year over year (up 65%), 62% of the total change. Trulicity declined 14%.
Operating profit was $8.4B, a 34.5% margin (down 6.6 points year over year). Of the extra revenue versus Q3 2025, 17% reached operating profit, below the 41% margin then. Total costs grew 54% against revenue growth of 39%. The fastest-growing cost line was Other operating costs (+306%). Net earnings were $6.5B, up 16% year over year. The effective tax rate was 23.3%.
Operating cash flow was $11.4B (up 29% year over year), 177% of net earnings. Non-cash charges added back $0.55B of depreciation and amortization and $0.20B of share-based compensation. Working capital and other items added $4.2B. Capital expenditures of $3.2B left free cash flow of $8.2B.
Questions
What was ELI Lilly's revenue in the third quarter 2026?
ELI Lilly (LLY) reported revenue of $24.4B for the third quarter 2026 (Q3 2026), +39% from a year earlier and +6% from the quarter before.
Was ELI Lilly profitable in the third quarter 2026?
Operating profit was $8.4B (34.5% of revenue) and net earnings $6.5B.
Source: ELI Lilly 10-Q on SEC EDGAR.